<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589628</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00000057</org_study_id>
    <nct_id>NCT00589628</nct_id>
  </id_info>
  <brief_title>Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis</brief_title>
  <official_title>Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Egla C. Rabinovich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Childhood Arthritis and Rheumatology Research Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to examine the efficacy of infliximab for the
      treatment of persistent uveitis in children. Participants (4-18 years of age) will be
      randomly assigned to either 5mg/kg or 10mg/kg dose of infliximab to be administered by
      intravenous infusion at four week intervals. Participant responses will be measured at at
      four to eight week intervals for up to ten months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric rheumatologists often use infliximab in the treatment of childhood uveitis, at this
      time there are no prospective studies for this use. Participants will be randomized to
      initial suggested dose of infliximab (5 mg/kg/dose vs 10 mg/kg/dose) and data will be
      collected prospectively with regard to ophthalmologic outcomes. Study participants will be
      followed for up to 10 months to determine efficacy and side effects, and an additional 30
      days for safety reports. Descriptive statistics will be gathered on participant demographics,
      uveitis characteristics, change in immunosuppressive medications, number of responders,
      ophthalmologic measures and change in corticosteroid dose during the study period. Initial to
      final dose will be examined by paired t-test. The proportion of responders in the 5 mg/kg
      initial dose group will be compared to the 10 mg/kg/dose by a Chi-square or Fisher's exact
      test, depending on numbers available. Predictors of response will be examined by logistic
      regression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of Infliximab on Uveitis Disease Activity.</measure>
    <time_frame>9 months</time_frame>
    <description>Number of subjects with improvement in uveitis, defined as a two step decrease in level of inflammation (as defined by SUN criteria, AC cells, vitreous haze) or decrease to grade 0. A grading scheme of 0 indicating (&lt;1 cell/ocular field) low levels of inflammation to 4+ indicating (&gt;50 cells/ocular field) indicating high levels of inflammation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Chronic Uveitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5mg/kg/dose of infliximab IV every 4 weeks for 9 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg/kg/dose of infliximab IV every 4 weeks for 9 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infliximab</intervention_name>
    <description>5mg/kg/dose IV at 4 week intervals</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infliximab</intervention_name>
    <description>10mg/kg/dose IV at 4 week intervals</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:.

          1. Ages 4 to 18 years old,

          2. Non-infectious uveitis

          3. Persistent uveitis uncontrolled by topical medications, or unacceptable side effects
             of topical medications.

          4. Failure of at least six weeks of treatment with a non-biological disease modifying
             agent such as methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine.

          5. Ability to provide informed consent (subject or parent/guardian)

          6. Onset of uveitis &lt; 16 years of age.

          7. Topical ophthalmologic treatments allowed.

          8. Systemic corticosteroid use at entry may be allowed.

          9. Willingness to use acceptable contraception if sexually active for the duration of the
             study and for 6 months after receiving the last infliximab infusion.

         10. Concomitant methotrexate must be taken at time of initiation of infliximab

         11. Participant must be able to cooperate for a non-sedated slit lamp exam and visual
             acuity examination.

         12. Negative Purified Protein Derivative (PPD) placed and read within 1 month of
             initiation of infliximab

         13. The screening laboratory test results must meet the following criteria:

               -  WBC (white blood cell count): within normal range for institution

               -  ANC (absolute neutrophil count): within normal range for institution

               -  Hemoglobin: greater than 10 grams/deciliter

               -  Platelets: within normal range for institution

               -  Serum Creatinine: within normal range for age

               -  AST - aspartate aminotransferase - within normal range for institution

               -  ALT - alanine aminotransferase- within normal range for institution

        Exclusion Criteria:

          1. Previous use of biologic medications for uveitis.

          2. Intraocular steroid injection or ophthalmologic surgery within the preceding 3 months.

          3. Uveitis due to trauma or intraocular surgery

          4. Females who are pregnant, nursing, or planning pregnancy within 6 months after the
             last infliximab infusion.

          5. Males who plan on fathering a child within 6 months after their last infliximab
             infusion.

          6. A history of a known allergy to murine products.

          7. Documentation of seropositivity for human immunodeficiency virus (HIV).

          8. Documentation of a positive test for hepatitis B surface antigen or hepatitis C

          9. A known history of a serious infection (e.g., hepatitis, pneumonia, or pyelonephritis)
             in the previous 3 months.

         10. An opportunistic infection (e.g., herpes zoster [shingles], cytomegalovirus,
             Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB)
             within 6 months prior to screening.

         11. A concomitant diagnosis or history of congestive heart failure.

         12. A history of lymphoproliferative disease.

         13. Any known malignancy or a history of malignancy.

         14. Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic,
             hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral
             disease.

         15. Use of any investigational drug within 30 days prior to screening or within five
             half-lives of the first dose of the investigational agent, whichever is longer.

         16. Presence of a transplanted solid organ.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Egla Rabinovich, MD. MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://carragroup.org</url>
    <description>Research Information. Click on current studies</description>
  </link>
  <reference>
    <citation>Heiligenhaus A, Foeldvari I, Edelsten C, Smith JR, Saurenmann RK, Bodaghi B, de Boer J, Graham E, Anton J, Kotaniemi K, Mackensen F, Minden K, Nielsen S, Rabinovich EC, Ramanan AV, Strand V; Multinational Interdisciplinary Working Group for Uveitis in Childhood. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res (Hoboken). 2012 Sep;64(9):1365-72. doi: 10.1002/acr.21674. Review.</citation>
    <PMID>22438273</PMID>
  </reference>
  <reference>
    <citation>Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol. 2007 Dec;144(6):844-849. Epub 2007 Oct 22.</citation>
    <PMID>17953940</PMID>
  </reference>
  <results_reference>
    <citation>Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, Feldman BM, Laxer RM, Schneider R, Silverman ED. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006 Aug;45(8):982-9. Epub 2006 Feb 3.</citation>
    <PMID>16461435</PMID>
  </results_reference>
  <results_reference>
    <citation>Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006 May;113(5):860-4.e2. Epub 2006 Mar 20.</citation>
    <PMID>16545455</PMID>
  </results_reference>
  <results_reference>
    <citation>Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006 Feb;113(2):308-14. Epub 2006 Jan 10.</citation>
    <PMID>16406545</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <results_first_submitted>February 21, 2013</results_first_submitted>
  <results_first_submitted_qc>August 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2013</results_first_posted>
  <last_update_submitted>August 22, 2013</last_update_submitted>
  <last_update_submitted_qc>August 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Egla C. Rabinovich</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Childhood</keyword>
  <keyword>Uveitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Infliximab 5 mg/kg</title>
          <description>5mg/kg/does of infliximab IV at 4 week intervals</description>
        </group>
        <group group_id="P2">
          <title>Infliximab 10 mg/kg</title>
          <description>10mg/kg/dose of infliximab Iv at 4 week intervals</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>5 mg/kg of Infliximab</title>
          <description>5mg/kg/does of infliximab IV at 4 week intervals</description>
        </group>
        <group group_id="B2">
          <title>10 mg/kg of Infliximab</title>
          <description>10mg/kg/dose of infliximab Iv at 4 week intervals</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effects of Infliximab on Uveitis Disease Activity.</title>
        <description>Number of subjects with improvement in uveitis, defined as a two step decrease in level of inflammation (as defined by SUN criteria, AC cells, vitreous haze) or decrease to grade 0. A grading scheme of 0 indicating (&lt;1 cell/ocular field) low levels of inflammation to 4+ indicating (&gt;50 cells/ocular field) indicating high levels of inflammation.</description>
        <time_frame>9 months</time_frame>
        <population>1 subject lost to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Infliximab 5mg/kg</title>
            <description>5mg/kg/does of infliximab IV at 4 week intervals</description>
          </group>
          <group group_id="O2">
            <title>Infliximab 10mg/kg</title>
            <description>10mg/kg/dose of infliximab Iv at 4 week intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Infliximab on Uveitis Disease Activity.</title>
          <description>Number of subjects with improvement in uveitis, defined as a two step decrease in level of inflammation (as defined by SUN criteria, AC cells, vitreous haze) or decrease to grade 0. A grading scheme of 0 indicating (&lt;1 cell/ocular field) low levels of inflammation to 4+ indicating (&gt;50 cells/ocular field) indicating high levels of inflammation.</description>
          <population>1 subject lost to follow up</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="6" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>5 mg/kg of Infliximab</title>
          <description>5mg/kg/does of infliximab IV at 4 week intervals</description>
        </group>
        <group group_id="E2">
          <title>10 mg/kg of Infliximab</title>
          <description>10mg/kg/dose of infliximab Iv at 4 week intervals</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>physician defined</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Hospitalization for a positive blood culture, but repeat negative and felt to be consistent with a contaminated culture. Subject also had myalgias and ear cellulitis. Refused further follow up</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>PI determined</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fever blister</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study recruitment was difficult and slow. Optimal number not achieved in this descriptive study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. C. Egla Rabinovich</name_or_title>
      <organization>Duke Health Systems</organization>
      <phone>919-668-0238</phone>
      <email>egla.rabinovich@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

